| Literature DB >> 21224856 |
M Aoki1, S Ishigami, Y Uenosono, T Arigami, Y Uchikado, Y Kita, H Kurahara, M Matsumoto, S Ueno, S Natsugoe.
Abstract
BACKGROUND: Bone morphogenetic protein-7 (BMP-7) is a signalling molecule belonging to the transforming growth factor--superfamily. Recent studies have demonstrated the clinical impact of BMP-7 expression in various human cancers. However, there have been few reports detailing this in gastric cancer.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21224856 PMCID: PMC3049585 DOI: 10.1038/sj.bjc.6606075
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Patient characteristics
|
| |
|---|---|
|
| |
| Male | 161 |
| Female | 72 |
|
| |
| Mean | 66 |
| Range | 31–85 |
|
| |
| Total gastrectomy | 124 |
| Distal | 75 |
| Proximal | 21 |
| Partial | 13 |
|
| |
| I | 70 |
| II | 45 |
| III | 63 |
| IV | 55 |
|
| |
| Differentiated | 118 |
| Undifferentiated | 115 |
Figure 1Expression of BMP-7 in clinical samples. Immunostaining of BMP-7 (original magnification, × 400): Examples of (A) noncancerous kidney tissue, (B) noncancerous gastric epithelium, (C) BMP-7-positive gastric cancer and (D) BMP-7-negative gastric cancer are shown. Staining is detected in cell membranes and the cytoplasm (A, C; they obviously stain brown).
Correlation between expression of BMP-7 and clinical factors
|
| |||
|---|---|---|---|
|
|
|
|
|
|
| |||
| <65 | 40 (48) | 44 | 0.08 |
| ⩾65 | 89 (60) | 60 | |
|
| |||
| Male | 94 (58) | 67 | 0.2 |
| Female | 35 (49) | 37 | |
|
| |||
| <50 mm | 40 (44) | 50 | 0.01 |
| ⩾50 mm | 89 (62) | 54 | |
|
| |||
| T1 (sm)/T2 (mp) | 85 (57) | 65 | 0.68 |
| T3 (ss)/T4 (se) | 44 (53) | 39 | |
|
| |||
| Yes | 87 (63) | 52 | <0.01 |
| No | 42 (45) | 52 | |
|
| |||
| Yes | 107 (61) | 69 | <0.01 |
| No | 22 (39) | 35 | |
|
| |||
| Yes | 88 (67) | 44 | <0.01 |
| No | 41 (41) | 60 | |
|
| |||
| Differentiated | 73 (62) | 45 | <0.05 |
| Undifferentiated | 56 (49) | 59 | |
Abbreviation: BMP-7=bone morphogenetic protein-7.
Figure 2Postoperative survival curves of patients according to their expression of BMP-7 in gastric cancer. The BMP-7-positive group had significantly lower overall survival than the BMP-7-negative group (P<0.01, log-rank test) (A). In the differentiated group, no significant difference was observed in overall survival (P=0.11, log-rank test) (B). In the undifferentiated group, the BMP-7-positive group had significantly lower overall survival than the BMP-7-negative group (P=0.01, log-rank test) (C).
Univariate and multivariate analysis of prognostic factor in gastric cancer
|
|
|
|
|
|
|---|---|---|---|---|
| Age | 0.4 | — | — | — |
| Gender | 0.88 | — | — | — |
| Histology | <0.01 | <0.05 | 1.893 | 1.021–3.510 |
| Depth | <0.01 | <0.01 | 3.239 | 1.650–6.361 |
| Tumour size | <0.01 | 0.34 | 1.518 | 0.641–3.595 |
| Nodal involvement | <0.01 | <0.01 | 3.868 | 1.450–10.321 |
| Lymphatic invasion | <0.01 | — | — | — |
| Venous invasion | <0.01 | 0.18 | 1.171 | 0.555–2.474 |
| BMP-7 | <0.01 | <0.01 | 2.934 | 1.524–5.648 |
Abbreviation: BMP-7=bone morphogenetic protein-7.